LivaNova LIVN
NASDAQ LIVN
$78.96 -1.74 (-2.16%)
As of: Sep 9, 2026 · 3:59 PM EDT

LivaNova (LIVN) Asset Writedowns and Impairment (2015 - 2026)

LivaNova's (LIVN) quarterly Asset Writedowns and Impairment came in at $1.1 million in Q1 2026, up 1.8% quarter-over-quarter from $1.1 million in Q3 2025.

Analysis

LivaNova (LIVN) Asset Writedowns and Impairment (2015 - 2026) Analysis & Trends

LivaNova has disclosed Asset Writedowns and Impairment across 9 years of filings, most recently posting $1.1 million for Q1 2026.

  • In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $2.2 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, down 80.72% from the prior year.
  • Asset Writedowns and Impairment came in at $1.1 million for Q1 2026 at LivaNova, up from $1.1 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $90.0 million in Q4 2023 to a low of $1.1 million in Q3 2025.
  • Average Asset Writedowns and Impairment over 4 years is $24.5 million, with a median of $3.4 million recorded in 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 183.04 Bn 177.44 Bn 7.27 Bn
2 Intuitive Surgical 125.02 Bn 119.81 Bn 1.96 Bn
3 Medtronic 117.84 Bn 109.02 Bn 6.34 Bn
4 Stryker 105.50 Bn 102.02 Bn 4.50 Bn
5 Boston Scientific 66.27 Bn 65.73 Bn 3.85 Bn
6 Edwards Lifesciences 49.60 Bn 45.35 Bn 1.35 Bn
7 Alcon 33.70 Bn 32.24 Bn 1.68 Bn
8 Dexcom 32.06 Bn 30.11 Bn 830.00 Mn
9 Steris 21.02 Bn 20.54 Bn 684.20 Mn
10 LivaNova 4.34 Bn 3.82 Bn 273.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 1.13 Mn
Sep 30, 2025 1.11 Mn
Jun 30, 2024 5.75 Mn
Dec 31, 2023 89.97 Mn
Dec 31, 2020 6.76 Mn
Dec 31, 2019 89.00 Mn
Jun 30, 2019 50.30 Mn
Dec 31, 2018 567,000.00
Dec 31, 2016 -19.38 Mn
Sep 30, 2016 19.32 Mn
Jul 24, 2015 2.06 Mn
Apr 24, 2015 448,000.00